CCNE1基因在卵巢高级别浆液性癌中的研究进展  

Research Progress of CCNE1 Gene in High-Grade Serous Ovarian Carcinoma

作　　者：刘艳[1] 卞伟[2] 肖虹(审校)[3] LIU Yan;BIAN Wei;XIAO Hong(The First Clinical Medical College,Shanxi Medical University,Taiyuan 030001,China;School of Basic Medical Science,Shanxi Medical University,Taiyuan 030001,China;Department of Pathology,The First Hospital of Shanxi Medical University,Taiyuan 030001,China)

机构地区：[1]山西医科大学第一临床医学院,太原030001 [2]山西医科大学基础医学院 [3]山西医科大学第一医院病理科

出　　处：《国际妇产科学杂志》2022年第3期286-290,共5页Journal of International Obstetrics and Gynecology

基　　金：山西省自然科学基金(201901D111210)。

摘　　要：细胞周期蛋白E1(Cyclin E1,CCNE1)基因扩增是卵巢高级别浆液性癌(high-grade serous ovarian carcinoma,HGSOC)最常见的拷贝数变异之一,扩增率为20%左右。CCNE1基因扩增不仅参与HGSOC的早期癌前病变,促进恶性肿瘤的发生、发展,还可引起细胞周期紊乱和染色体不稳定,从而增加HGSOC的铂类耐药性和复发率,最终导致患者的化疗效果不佳和预后较差。为改善CCNE1扩增的HGSOC患者的预后和生活质量,在暂时没有CCNE1扩增的HGSOC的靶向治疗药物的情况下,使用细胞周期蛋白依赖性激酶2(cyclin-dependent kinases 2,CDK2)小分子抑制剂或者多腺苷二磷酸核糖聚合酶[poly(ADP-ribose)polymerase,PARP]抑制剂与其他药物联合治疗,一定程度上能有效地抑制肿瘤细胞的增殖活性,促进肿瘤细胞死亡。因此,从CCNE1扩增对HGSOC的早期发病机制的影响和产生铂类耐药的角度上来说,CCNE1基因有望成为HGSOC的潜在治疗靶标和预后评价生物学指标,在改善患者的治疗和预后方面具有重要意义。CyclinE1(CCNE1)gene amplification is one of the most common copy number variations in high-grade serous ovarian carcinoma(HGSOC),with an amplification rate of about 20%.CCNE1 gene amplification not only participates in the early precancerous lesions of HGSOC and promotes the occurrence and development of malignant tumors,but also causes cell cycle disorder and chromosome instability,thus increasing platinum resistance and recurrence rate of HGSOC,and ultimately leading to poor chemotherapy effect and poor prognosis of patients.In order to improve the prognosis and quality of life of patients with CCNE1-amplified HGSOC,cyclin-dependent kinases 2(CDK2)small molecule inhibitors or poly(ADP-ribose)polymerase(PARP)inhibitors in combination with other drugs are used to treat CCNE1-amplified HGSOC in the absence of targeted drugs for CCNE1-amplified HGSOC.To a certain extent,it can effectively inhibit the proliferation of tumor cells and promote the death of tumor cells.Therefore,CCNE1 gene is expected to become a potential therapeutic target and prognostic biological indicator of HGSOC from the perspective of the influence of CCNE1 amplification on the early pathogenesis of HGSOC and the generation of platinum resistance,which is of great significance to improve the treatment and prognosis of patients.

关 键 词：卵巢肿瘤 细胞周期蛋白E 基因扩增 药物疗法 预后 卵巢高级别浆液性癌 

分 类 号：R737.31[医药卫生—肿瘤]